Clinical Trials in Slovakia

• Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamo… Recruiting
  2023-506308-24-00 Phase II/III Recurrent or metastatic head and neck squamous cell carcinom… Exelixis Inc.
• Phase 3 extension study to evaluate long-term safety of two regimens of ianalumab in participants with systemic lupus erythematosus (SIRIUS-… Recruiting
  2023-505929-14-00 Phase III Systemic Lupus Erythematosus Novartis Pharma AG
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 Phase III Nervous system diseases Sanofi-Aventis Recherche & Developpement
• A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w… Recruiting
  2023-504151-27-00 Phase III Psychosis associated with Alzheimer’s Disease Karuna Therapeutics Inc.
• RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previousl… Recruiting
  2022-500031-37-00 Phase III ​ stage IA/IIA Hodgkin lymphoma University College London
• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 Phase III Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer Merck Sharp & Dohme LLC
• A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis (ELFIDENCE) Recruiting
  2023-505251-43-00 Phase III Primary Biliary Cholangitis Ipsen Bioscience Inc.
• A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adul… Recruiting
  2023-504863-17-00 Phase III 1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutan… Biogen Idec Research Limited
• Prophylaxis Study of Marstacimab in Pediatric Hemophilia Participants With or Without Inhibitors Recruiting
  2022-500495-65-00 Phase III Haemophilia Pfizer Inc.
• Randomized trial comparing efficacy and safety of initial triple therapy including parenteral treprostinil to initial double oral therapy in… Recruiting
  2023-504351-26-01 Phase III/IV Pulmonary arterial hypertension (group I) Aop Orphan Pharmaceuticals GmbH
• A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting
  2023-503224-66-00 Phase III Atrial Fibrillation Anthos Therapeutics Inc.
• Hidradenitis Suppurativa: Evaluation of Upadacitinib in Adult and Adolescent Subjects Recruiting
  2023-503661-28-00 Phase III Hidradenitis Suppurativa Abbvie Deutschland GmbH & Co. KG
• A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) … Recruiting
  2022-502160-20-00 Phase III Idiopathic Immune Complex Mediated Membranoproliferative Glo… Novartis Pharma AG
• A study to assess the long-term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammat… Recruiting
  2022-502851-79-00 Phase III Active Idiopathic Inflammatory Myopathy (IIM) Argenx
• A study of different dose levels of FluBHPVE6E7 or placebo in women infected with the virus Human Papilloma Type 16 (HPV 16). Recruiting
  2024-515535-30-00 Phase I (Other) Treatment of human papilloma virus (HPV) associated infectio… Bluesky Immunotherapies GmbH
• An European multinational study of a personalized approach of human albumin administration in patients with cirrhosis of the liver and compl… Recruiting
  2022-501006-34-01 Phase III Liver cirrhosis European Foundation For The Study Of Chronic Liver Failure; Odense University Ho…
• Long-term safety and tolerability of inclisiran in participants with heterozygous familial hypercholesterolaemia or homozygous familial hype… Recruiting
  2023-507278-41-00 Phase III Familial hypercholsterolemia Novartis Pharma AG
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cut… Recruiting
  2023-505634-94-00 Phase II/III Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lu… Biogen Idec Research Limited
• A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting
  2024-514180-25-00 Phase III unresectable or metastatic HER2+ colorectal cancer Seagen Inc.
• Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors Recruiting
  2022-500470-33-00 Phase III Haemophilia Pfizer Inc.
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 Phase III chronic myelogenous leukemia (CML) or Philadelphia Chromosom… Novartis Pharma AG
• Effects of N-Acetyl-L-Leucine on Niemann-Pick disease type C (NPC): A Phase III, randomized, placebo-controlled, double-blind, crossover stu… Recruiting
  2023-510278-14-00 Phase III Niemann-Pick disease type C Intrabio Limited
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 Phase III Adenocarcinoma of the prostate Unicancer
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 Phase III Acute myocardial infarction (AMI) Viatris Innovation GmbH

Showing 169–192 of 479 trials